Jen Barnes
Director, Commercialisation and Research Translation; Director, Burnet Diagnostics Initiative
Working groups
Background
Jen has a diverse background spanning research, pathology, the clinical interface, academia, and industry.
Beginning her career in academic research before transitioning into a large multinational in-vitro diagnostics (IVD) company, Jen discovered her passion at the intersection of science, innovation, and impact.
She thrives on translating groundbreaking research and product development into commercially viable, accessible solutions that deliver both social impact and financial return. Over the course of her career, she has led several start-ups, overseen business development activities, and shaped commercialisation strategies across the health and life sciences sector.
Jen joined Burnet Institute to establish and lead the Burnet Diagnostics Initiative and now serves as Director of Commercialisation and Research Translation. In this role, she focuses on strengthening quality systems, stakeholder engagement, and industry partnerships — recognising that Burnet’s discoveries can achieve far greater impact when science, business and community come together.
Appointments
- Director, Commercialisation and Research Translation
- Director, Burnet Diagnostics Initiative
- Mentor, Franklin Women
- Expert Panel Subgroup Member, NSW Medical Device Fund
Current projects
View 2 moreDevelopment of a novel antibody for treatment and prevention of respiratory disease
We’re developing a novel class of antibody and delivery technologies to provide enhanced protection and therapeutic performance for coronaviruses and other respiratory infections.
Diagnosis of active syphilis
We're developing point-of-care diagnostics for active syphilis, aiming to transform syphilis management globally and contribute to World Health Organization goals.
Liver health screening test
A rapid point-of-care (POC) test for liver disease biomarkers could improve the management of acute and chronic liver disease and reduce the progression to liver cancer in Australia and globally.
News and features
View 2 more
Burnet partners with Atomo to develop Australia’s first syphilis self-test
Burnet partners with Atomo on a new syphilis point-of-care test, backed by the Australian Government.
Burnext accelerator program recipients
